Expand the diversity of trials available at the site by offering additional:
- Treatment Phases (e.g., phases I – III trials);
- Treatment types to reflect diversity of patient population (e.g., more diversified disease portfolio or broader mix of surgery, radiotherapy and chemotherapy trials);
- Other types of trials (including prevention, quality of life, symptom control, and correlative trials).
- Review of the Attributes: Part I
- Review of the Attributes: Part II
- Trials with Biospecimen and Biomarker Components
- Biospecimen Collection and Use
Office of Biorepositories and Biospecimen Research, NCI
OBBR, a division of the National Cancer Institute (NCI), is dedicated to researching the impact of biospecimen processing studies, developing and distributing guidelines for biospecimen research, and developing new technology and standards for biorepositories.
Best Practice for Biospecimen Resources, NCI
These voluntary guidelines are available online for free and provide an outline of how to incorporate Best Practices into a site’s internal procedures. The guidelines are divided into two broad areas including “Technical and Operational Best Practices” and “Ethical, Legal, and Policy Best Practices.”